Newsletter
Oct 13, 2026
•
5 min read
Plus a first-in-class herpes approval, an alpha-emitter Phase 3 win, and three biotechs queuing for IPOs.
Oct 9, 2026
Plus Zealand’s amylin data in diabetes, Tukysa moves up a line, and TRexBio prices at $14.
Oct 8, 2026
4 min read
Plus Halozyme blocks SC Keytruda in eight countries, and Caribou pulls the plug.
Oct 7, 2026
Plus Epkinly's frontline DLBCL win and ArriVent's 57% plunge.
Oct 6, 2026
Vaxcyte's pivotal print sent PCVX flying, Shionogi paid $2B for IntraBio, and Genentech bought Alector a runway.
Oct 5, 2026
Lilly takes Jaypirca first-line, and a sell-side desk crowns Genmab’s ovarian ADC.
Oct 2, 2026
Survodutide wins Phase 3 and still disappoints, while Lilly walks away from Foghorn.
Oct 1, 2026
Plus Lilly's amylin cocktail edges its own triple-G, and a liver death shadows Bristol's fibrosis bet.
Sep 30, 2026
Year-four Huntington's data wobbles, full TRIUMPH-2 lands at EASD, and Merck's TL1A clears HS.
Sep 29, 2026
Merck's split-screen Monday, and Novo pays $300M upfront for a weekly GLP-1 pill.
Sep 28, 2026
Novo licenses monthly-shot tech, Merck's kidney doublet beats its PDUFA, EASD opens in Milan.
Sep 25, 2026
Merck's $3B eye bet clears its pivotal test, Lilly's weekly insulin lands, Overton parries.
Sep 24, 2026
Enveda banks $311M at a ~$2B valuation, and Roche's monthly IgAN shot hits in Phase 3.
Sep 23, 2026
Celldex's hives double comes with an anaphylaxis asterisk, and Amgen squeezes a Phase 3 win out of Horizon.
Sep 22, 2026
FDA staff go easy on Galleri, Pfizer's MFN fine print leaks, and Bayer sells Stivarga.
Sep 21, 2026
Xenon sheds 23% on a psychiatry pause, and Beacon lands the first pivotal win in XLRP.
Sep 18, 2026
Ultragenyx wins full approval two days early, and Roche buys 300,000 shots on goal.
Sep 17, 2026
A TREM2 flop, a brain-shuttle cheque, and two years of kidney receipts from Vera.
Sep 16, 2026
Plus Curium's first Lutathera lookalike, TrialBlazer opens, and J&J's depression drug misses again.
Sep 15, 2026
A CTLA-4 doubles survival in squamous lung, and Apollo circles DePuy Synthes.
Sep 14, 2026
GSK and Roche land matching survival wins in Seoul; Etcamah flunks first-line breast.
Sep 10, 2026
Bayer takes first-line HER2 lung, Solstice debuts big, and WCLC is two days out.
Sep 9, 2026
A survival win, a 10% drawdown, and an oral HAE drug at 83%.
Sep 8, 2026
Novo scraps two more ziltivekimab trials, and FDA approves a drug off a blood test.
Sep 4, 2026
An ultra-rare approval, a 74% response rate, and a licence signed before Phase 1.
